Tyme Technologies Inc (TYME) USD0.0001
TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.